Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Replimune Group, Inc.REPL · Entity 4707 | Director · Chief Executive Officer | August 10, 2026 | August 12, 2026 |
| Revolution Medicines, Inc.RVMD · Entity 606 | Director | June 29, 2026 | July 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Replimune Group, Inc.
Report date August 10, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 708,151 |
Reported balance
After 2026-08-10 transaction · row 1
1 source rowRow 1 · 2026-08-10 · Sale · Disposed 39,341 · Balance 708,151 F1: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the vesting of the Reporting Person's performance-based restricted stock units (the "PSUs"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the PSUs were granted and does not represent a discretionary sale by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the vesting of the Reporting Person's performance-based restricted stock units (the "PSUs"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the PSUs were granted and does not represent a discretionary sale by the Reporting Person.
Revolution Medicines, Inc.
Report date June 29, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,656 |
Last balance in matching sequence
After 2026-06-29 transaction · row 10
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
10 source rowsRow 1 · 2026-06-29 · Exercise / conversion · Acquired 2,955 · Balance 27,236 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. F2: Includes 1,191 restricted stock units. Row 2 · 2026-06-29 · Sale · Disposed 300 · Balance 26,936 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. F3: The transaction was executed in multiple trades in prices ranging from $182.93 to $183.54, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2: Includes 1,191 restricted stock units. Row 3 · 2026-06-29 · Sale · Disposed 900 · Balance 26,036 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. F4: The transaction was executed in multiple trades in prices ranging from $184.08 to $184.98, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2: Includes 1,191 restricted stock units. Row 4 · 2026-06-29 · Sale · Disposed 1,100 · Balance 24,936 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. F5: The transaction was executed in multiple trades in prices ranging from $185.37 to $186.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2: Includes 1,191 restricted stock units. Row 5 · 2026-06-29 · Sale · Disposed 858 · Balance 24,078 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. F6: The transaction was executed in multiple trades in prices ranging from $186.38 to $187.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2: Includes 1,191 restricted stock units. Row 6 · 2026-06-29 · Sale · Disposed 300 · Balance 23,778 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. F7: The transaction was executed in multiple trades in prices ranging from $187.46to $188.27, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2: Includes 1,191 restricted stock units. Row 7 · 2026-06-29 · Sale · Disposed 100 · Balance 23,678 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. F2: Includes 1,191 restricted stock units. Row 8 · 2026-06-29 · Sale · Disposed 600 · Balance 23,078 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. F8: The transaction was executed in multiple trades in prices ranging from $190.44 to $190.74, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2: Includes 1,191 restricted stock units. Row 9 · 2026-06-29 · Sale · Disposed 541 · Balance 22,537 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. F9: The transaction was executed in multiple trades in prices ranging from $191.47 to $192.40, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2: Includes 1,191 restricted stock units. Row 10 · 2026-06-29 · Sale · Disposed 881 · Balance 21,656 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. F10: The transaction was executed in multiple trades in prices ranging from $192.55 to $192.64, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2: Includes 1,191 restricted stock units. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.54 · Expires 2034-06-19 | Direct | 13,000 |
Reported balance
After 2026-06-29 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-06-29 · Exercise / conversion · Disposed 2,955 · Balance 13,000 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. F11: Fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026.
F2: Includes 1,191 restricted stock units.
F3: The transaction was executed in multiple trades in prices ranging from $182.93 to $183.54, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4: The transaction was executed in multiple trades in prices ranging from $184.08 to $184.98, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F5: The transaction was executed in multiple trades in prices ranging from $185.37 to $186.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F6: The transaction was executed in multiple trades in prices ranging from $186.38 to $187.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F7: The transaction was executed in multiple trades in prices ranging from $187.46to $188.27, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F8: The transaction was executed in multiple trades in prices ranging from $190.44 to $190.74, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F9: The transaction was executed in multiple trades in prices ranging from $191.47 to $192.40, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F10: The transaction was executed in multiple trades in prices ranging from $192.55 to $192.64, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F11: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2026 Filed Aug 12, 2026 21:07 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 39,341 | $12.97 | $510,252.77 |
DisclosureSEC source: 0001104659-26-095012 · tm2623037-4_4seq1.xml · nonDerivative · entry 1 Patel Sushil · CIK 0001860609 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 708,151 F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the vesting of the Reporting Person's performance-based restricted stock units (the "PSUs"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the PSUs were granted and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 22:25 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,955 | $0.00 Strike: $37.54 | $0.00 |
DisclosureSEC source: 0001610717-26-000311 · form4.xml · derivative · entry 11 Patel Sushil · CIK 0001860609 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 2,955 shares Expires 2034-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. F11 · derivative.exercise_date: Fully vested. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 22:25 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 881 | $192.61 | $169,692.85 |
DisclosureSEC source: 0001610717-26-000311 · form4.xml · nonDerivative · entry 10 Patel Sushil · CIK 0001860609 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,656 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. F10 · price: The transaction was executed in multiple trades in prices ranging from $192.55 to $192.64, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 1,191 restricted stock units. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 22:25 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 541 | $191.87 | $103,799.56 |
DisclosureSEC source: 0001610717-26-000311 · form4.xml · nonDerivative · entry 9 Patel Sushil · CIK 0001860609 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,537 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. F9 · price: The transaction was executed in multiple trades in prices ranging from $191.47 to $192.40, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 1,191 restricted stock units. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 22:25 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 600 | $190.55 | $114,327.00 |
DisclosureSEC source: 0001610717-26-000311 · form4.xml · nonDerivative · entry 8 Patel Sushil · CIK 0001860609 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,078 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. F8 · price: The transaction was executed in multiple trades in prices ranging from $190.44 to $190.74, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 1,191 restricted stock units. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 22:25 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 100 | $188.57 | $18,857.00 |
DisclosureSEC source: 0001610717-26-000311 · form4.xml · nonDerivative · entry 7 Patel Sushil · CIK 0001860609 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,678 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. F2 · balance_after: Includes 1,191 restricted stock units. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 22:25 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 300 | $187.83 | $56,348.01 |
DisclosureSEC source: 0001610717-26-000311 · form4.xml · nonDerivative · entry 6 Patel Sushil · CIK 0001860609 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,778 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. F7 · price: The transaction was executed in multiple trades in prices ranging from $187.46to $188.27, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 1,191 restricted stock units. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 22:25 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 858 | $186.92 | $160,373.67 |
DisclosureSEC source: 0001610717-26-000311 · form4.xml · nonDerivative · entry 5 Patel Sushil · CIK 0001860609 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,078 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. F6 · price: The transaction was executed in multiple trades in prices ranging from $186.38 to $187.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 1,191 restricted stock units. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 22:25 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,100 | $185.90 | $204,489.01 |
DisclosureSEC source: 0001610717-26-000311 · form4.xml · nonDerivative · entry 4 Patel Sushil · CIK 0001860609 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,936 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. F5 · price: The transaction was executed in multiple trades in prices ranging from $185.37 to $186.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 1,191 restricted stock units. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 22:25 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 900 | $184.59 | $166,128.21 |
DisclosureSEC source: 0001610717-26-000311 · form4.xml · nonDerivative · entry 3 Patel Sushil · CIK 0001860609 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,036 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. F4 · price: The transaction was executed in multiple trades in prices ranging from $184.08 to $184.98, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 1,191 restricted stock units. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 22:25 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 300 | $183.17 | $54,951.99 |
DisclosureSEC source: 0001610717-26-000311 · form4.xml · nonDerivative · entry 2 Patel Sushil · CIK 0001860609 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,936 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. F3 · price: The transaction was executed in multiple trades in prices ranging from $182.93 to $183.54, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 1,191 restricted stock units. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 22:25 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 2,955 | $37.54 | $110,930.70 |
DisclosureSEC source: 0001610717-26-000311 · form4.xml · nonDerivative · entry 1 Patel Sushil · CIK 0001860609 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,236 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. F2 · balance_after: Includes 1,191 restricted stock units. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:43 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 3,127 | $0.00 Strike: $162.99 | $0.00 |
DisclosureSEC source: 0001610717-26-000284 · form4.xml · derivative · entry 2 Patel Sushil · CIK 0001860609 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,127 Underlying: Common Stock · 3,127 shares Expires 2036-06-18 F2 · derivative.exercise_date: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 18, 2026 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:43 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 1,191 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000284 · form4.xml · nonDerivative · entry 1 Patel Sushil · CIK 0001860609 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,281 F1 · acquired: Includes 1,191 restricted stock units. F1 · balance_after: Includes 1,191 restricted stock units. Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:15 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 37,324 | $5.08 | $189,605.92 |
DisclosureSEC source: 0001104659-26-064519 · tm2615137-2_4seq1.xml · nonDerivative · entry 1 Patel Sushil · CIK 0001860609 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 747,492 F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $5.01 to $5.08 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range. Read SEC document |
| April 01, 2026 Filed Apr 8, 2026 01:09 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 376,860 | $0.00 Strike: $7.61 | $0.00 |
DisclosureSEC source: 0001104659-26-040571 · tm2611350-11_4seq1.xml · derivative · entry 2 Patel Sushil · CIK 0001860609 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 376,860 Underlying: Common Stock · 376,860 shares Expires 2036-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2027, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2026 Filed Apr 8, 2026 01:09 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 251,240 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-040571 · tm2611350-11_4seq1.xml · nonDerivative · entry 1 Patel Sushil · CIK 0001860609 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 784,816 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2027 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2030, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| December 19, 2025 Filed Dec 19, 2025 22:14 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-123290 · tm2533977-5_4seq1.xml · nonDerivative · entry 1 Patel Sushil · CIK 0001860609 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 533,576 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 50% of the RSUs will vest on November 15, 2026 and 50% of the RSUs will vest on November 15, 2027, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 21:30 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 10,000 | $11.13 | $111,300.00 |
DisclosureSEC source: 0001104659-25-118483 · tm2532752-1_4seq1.xml · nonDerivative · entry 1 Patel Sushil · CIK 0001860609 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 333,576 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 2, 2025, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.00 to $11.26. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 333,576 shares of the Issuer's common stock, including restricted stock units. The reporting person also holds options to acquire an aggregate of 753,750 shares of the Issuer's common stock, 331,353 of which are exercisable as of the date hereof. Read SEC document |
| June 26, 2025 Filed Jun 30, 2025 20:27 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 11,574 | $0.00 Strike: $37.48 | $0.00 |
DisclosureSEC source: 0001610717-25-000272 · form4.xml · derivative · entry 2 Patel Sushil · CIK 0001860609 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,574 Underlying: Common Stock · 11,574 shares Expires 2035-06-26 F2 · derivative.exercise_date: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 26, 2025 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date. Read SEC document |
| June 26, 2025 Filed Jun 30, 2025 20:27 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 3,142 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000272 · form4.xml · nonDerivative · entry 1 Patel Sushil · CIK 0001860609 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,090 F1 · acquired: Includes 4,017 Restricted Stock Units. F1 · balance_after: Includes 4,017 Restricted Stock Units. Read SEC document |
| May 20, 2025 Filed May 23, 2025 01:44 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 25,105 | $8.06 | $202,346.30 |
DisclosureSEC source: 0001104659-25-052143 · tm2515608-4_4seq1.xml · nonDerivative · entry 1 Patel Sushil · CIK 0001860609 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 343,576 F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $8.05 to $8.80 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range. Read SEC document |
| April 01, 2025 Filed Apr 4, 2025 00:06 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $8.40 | $0.00 |
DisclosureSEC source: 0001104659-25-031835 · tm2511407-11_4seq1.xml · derivative · entry 2 Patel Sushil · CIK 0001860609 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2035-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2026, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2025 Filed Apr 4, 2025 00:06 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 166,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-031835 · tm2511407-11_4seq1.xml · nonDerivative · entry 1 Patel Sushil · CIK 0001860609 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 368,681 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2026 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2029, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| December 16, 2024 Filed Dec 19, 2024 02:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 10,000 | $12.42 | $124,200.00 |
DisclosureSEC source: 0001104659-24-129864 · tm2431484-1_4seq1.xml · nonDerivative · entry 1 Patel Sushil · CIK 0001860609 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 202,014 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on April 3, 2024, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.20 to $12.62. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 202,014 shares of the Issuer's common stock, including restricted stock units. The reporting person also holds options to acquire an aggregate of 513,750 shares of the Issuer's common stock, 189,478 of which are exercisable as of the date hereof. Read SEC document |
| October 31, 2024 Filed Nov 4, 2024 21:05 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $24.84 | $0.00 |
DisclosureSEC source: 0001610717-24-000516 · form4.xml · derivative · entry 3 Patel Sushil · CIK 0001860609 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,400 Underlying: Common Stock · 5,000 shares Expires 2033-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on September 7, 2023. Read SEC document |
| October 31, 2024 Filed Nov 4, 2024 21:05 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 5,000 | $54.14 | $270,714.50 |
DisclosureSEC source: 0001610717-24-000516 · form4.xml · nonDerivative · entry 2 Patel Sushil · CIK 0001860609 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,948 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on September 7, 2023. F3 · price: The transaction was executed in multiple trades in prices ranging from $54.00 to $54.30, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 7,748 restricted stock units. Read SEC document |
| October 31, 2024 Filed Nov 4, 2024 21:05 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 5,000 | $24.84 | $124,200.00 |
DisclosureSEC source: 0001610717-24-000516 · form4.xml · nonDerivative · entry 1 Patel Sushil · CIK 0001860609 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,948 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on September 7, 2023. F2 · balance_after: Includes 7,748 restricted stock units. Read SEC document |
| July 09, 2024 Filed Jul 10, 2024 20:36 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,155 | $0.00 Strike: $16.80 | $0.00 |
DisclosureSEC source: 0001610717-24-000394 · form4.xml · derivative · entry 3 Patel Sushil · CIK 0001860609 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,490 Underlying: Common Stock · 2,155 shares Expires 2032-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on September 7, 2023. F3 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest with respect to 1/36 of the shares subject thereto on each monthly anniversary of June 16, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| July 09, 2024 Filed Jul 10, 2024 20:36 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,155 | $44.00 | $94,820.00 |
DisclosureSEC source: 0001610717-24-000394 · form4.xml · nonDerivative · entry 2 Patel Sushil · CIK 0001860609 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,948 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on September 7, 2023. F2 · balance_after: Includes 8,623 restricted stock units. Read SEC document |
| July 09, 2024 Filed Jul 10, 2024 20:36 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 2,155 | $16.80 | $36,204.00 |
DisclosureSEC source: 0001610717-24-000394 · form4.xml · nonDerivative · entry 1 Patel Sushil · CIK 0001860609 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on September 7, 2023. F2 · balance_after: Includes 8,623 restricted stock units. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:22 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 16,700 | $0.00 Strike: $37.54 | $0.00 |
DisclosureSEC source: 0001610717-24-000361 · form4.xml · derivative · entry 2 Patel Sushil · CIK 0001860609 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,700 Underlying: Common Stock · 16,700 shares Expires 2034-06-19 F2 · derivative.exercise_date: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 20, 2024 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:22 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 4,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000361 · form4.xml · nonDerivative · entry 1 Patel Sushil · CIK 0001860609 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,500 F1 · balance_after: Includes 9,175 Restricted Stock Units. Read SEC document |
| June 20, 2024 Filed Jun 28, 2024 21:06 UTC Amendment | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 15,955 | $0.00 Strike: $37.54 | $0.00 |
DisclosureSEC source: 0001610717-24-000374 · form4.xml · derivative · entry 2 Patel Sushil · CIK 0001860609 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,955 Underlying: Common Stock · 15,955 shares Expires 2034-06-19 F2 · derivative.exercise_date: Shares subject to the Stock Option shall vest in full on the earlier of (i) the first anniversary of June 20, 2024 or (ii) immediately prior to the Issuer's annual meeting of stockholders following the date of grant, subject to the Reporting Person continuing in service through the vesting date. Read SEC document |
| June 20, 2024 Filed Jun 28, 2024 21:06 UTC Amendment | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 4,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000374 · form4.xml · nonDerivative · entry 1 Patel Sushil · CIK 0001860609 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,948 F1 · balance_after: Includes 8,623 restricted stock units ("RSUs"). Read SEC document |
| May 16, 2024 Filed May 21, 2024 00:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 20,194 | $6.47 | $130,655.18 |
DisclosureSEC source: 0001104659-24-063559 · tm2414961-2_4seq1.xml · nonDerivative · entry 1 Patel Sushil · CIK 0001860609 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,014 F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $6.46 to $6.56 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range. Read SEC document |
| April 10, 2024 Filed Apr 12, 2024 20:23 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,155 | $0.00 Strike: $16.80 | $0.00 |
DisclosureSEC source: 0001610717-24-000205 · form4.xml · derivative · entry 3 Patel Sushil · CIK 0001860609 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,645 Underlying: Common Stock · 2,155 shares Expires 2032-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on September 7, 2023. F3 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest with respect to 1/36 of the shares subject thereto on each monthly anniversary of June 16, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| April 10, 2024 Filed Apr 12, 2024 20:23 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,155 | $37.00 | $79,735.00 |
DisclosureSEC source: 0001610717-24-000205 · form4.xml · nonDerivative · entry 2 Patel Sushil · CIK 0001860609 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,700 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on September 7, 2023. F2 · balance_after: Includes 10,450 restricted stock units. Read SEC document |
| April 10, 2024 Filed Apr 12, 2024 20:23 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 2,155 | $16.80 | $36,204.00 |
DisclosureSEC source: 0001610717-24-000205 · form4.xml · nonDerivative · entry 1 Patel Sushil · CIK 0001860609 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,855 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on September 7, 2023. F2 · balance_after: Includes 10,450 restricted stock units. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:03 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $7.73 | $0.00 |
DisclosureSEC source: 0001104659-24-043258 · tm2410652-11_4seq1.xml · derivative · entry 2 Patel Sushil · CIK 0001860609 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2034-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2025, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:03 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 83,335 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-043258 · tm2410652-11_4seq1.xml · nonDerivative · entry 1 Patel Sushil · CIK 0001860609 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,208 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2025 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2028, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| June 13, 2023 Filed Jun 16, 2023 01:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 553 | $23.44 | $12,962.32 |
DisclosureSEC source: 0001104659-23-071772 · tm2318878-1_4seq1.xml · nonDerivative · entry 2 Patel Sushil · CIK 0001860609 · Chief Strategy Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 148,873 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 15, 2023, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.29 to $23.53. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F4 · balance_after: Following the sales reported on this form 4, the reporting person continues to beneficially own 148,873 shares of the Issuer's common stock. The reporting person also holds options to acquire an aggregate of 263,750 shares of the Issuer's common stock, 88,072 of which are exercisable as of the date hereof. Read SEC document |
| June 13, 2023 Filed Jun 16, 2023 01:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 5,145 | $24.11 | $124,045.95 |
DisclosureSEC source: 0001104659-23-071772 · tm2318878-1_4seq1.xml · nonDerivative · entry 1 Patel Sushil · CIK 0001860609 · Chief Strategy Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 149,426 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 15, 2023, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.80 to $24.54. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:14 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 18,400 | $0.00 Strike: $24.84 | $0.00 |
DisclosureSEC source: 0001610717-23-000131 · form4.xml · derivative · entry 2 Patel Sushil · CIK 0001860609 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,400 Underlying: Common Stock · 18,400 shares Expires 2033-06-07 F2 · derivative.exercise_date: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 8, 2023 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:14 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 5,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000131 · form4.xml · nonDerivative · entry 1 Patel Sushil · CIK 0001860609 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,700 F1 · balance_after: Includes 13,950 Restricted Stock Units. Read SEC document |
| May 16, 2023 Filed May 19, 2023 00:36 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 15,575 | $18.05 | $281,128.75 |
DisclosureSEC source: 0001104659-23-062378 · tm2316199-9_4seq1.xml · nonDerivative · entry 1 Patel Sushil · CIK 0001860609 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,571 F1 · shares: Represents shares of the Issuer's common stock sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreement under which the RSU was granted and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.05 to $18.23. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 01, 2023 Filed Apr 5, 2023 00:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $17.66 | $0.00 |
DisclosureSEC source: 0001104659-23-041719 · tm2311410-3_4seq1.xml · derivative · entry 2 Patel Sushil · CIK 0001860609 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2033-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2024, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2023 Filed Apr 5, 2023 00:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-041719 · tm2311410-3_4seq1.xml · nonDerivative · entry 1 Patel Sushil · CIK 0001860609 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,146 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2024 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2027, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 21:06 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 36,800 | $0.00 Strike: $16.80 | $0.00 |
DisclosureSEC source: 0001567619-22-013113 · doc1.xml · derivative · entry 2 Patel Sushil · CIK 0001860609 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,800 Underlying: Common Stock · 36,800 shares Expires 2032-06-15 F2 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest with respect to 1/36 of the shares subject thereto on each monthly anniversary of June 16, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 21:06 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-013113 · doc1.xml · nonDerivative · entry 1 Patel Sushil · CIK 0001860609 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 F1 · balance_after: Includes 10,500 Restricted Stock Units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.